

## DAFTAR PUSTAKA

- Akram, M., Iqbal, M., Daniyal, M., Khan, A.U., 2017. Awareness and current knowledge of breast cancer. *Biol Res* 50: 33.
- Anywar, G.U., Kakudidi, E., Oryem-Origa, H., Schubert, A., Jassoy, C., 2022. Cytotoxicity of medicinal plant species used by traditional healers in treating people suffering from HIV/AIDS in Uganda. *Front Toxicol* 4: 832780.
- Arasavelli, A.M., Raghava Sharma, G.V., Vidavalur, S., 2016. Design, synthesis, and anticancer activity of novel aryl/heteroaryl chalcone derivatives. *Heterocycl Commun* 22: 1–5.
- Bagul, C., Rao, G.K., Makani, V.K.K., Tamboli, J.R., Pal-Bhadra, M., Kamal, A., 2017. Synthesis and biological evaluation of chalcone-linked pyrazolo[1,5-a]pyrimidines as potential anticancer agents. *Med Chem Commun* 8: 1810–1816.
- Bandeira, N.P., Lemos, T., Santos, H., *et al.*, 2019. Synthesis, structural characterization, and cytotoxic evaluation of chalcone derivatives. *Med Chem Res* 28: 2037–2049.
- Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M.H., Moradi-Kalbolandi, S., Safari, E., Farahmand, L., 2020. Breast cancer: biology, biomarkers, and treatments. *Int Immunopharmacol* 84: 106535.
- Bi, J., Wu, Z., Zhang, X., Zeng, T., *et al.*, 2023. TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. *Nat Commun* 14: 2342.
- Brunelle, J.K., Zhang, B., 2010. Apoptosis assays for quantifying the bioactivity of anticancer drug products. *Drug Resist Updat* 13: 172–179.
- Bukhari, S.N.A., Jasamai, M., Jantan, I., 2012. Synthesis and biological evaluation of chalcone derivatives (mini review). *Mini Rev Med Chem* 12: 1394–1403.
- Chagas, C.M., Moss, S., Alisaraie, L., 2018. Drug metabolites and their effects on the development of adverse reactions: revisiting lipinski's rule of five. *Int J Pharm* 549: 133–149.
- Chawapun, P., Khamto, N., Utama, K., Siriphong, S., Dechsupa, N., Kantapan, J., Meerak, J., Meepowpan, P., Sangthong, P., 2024. Synthesis and biological evaluation of imidazolium conjugated with dimethylcardamonin (DMC) as a novel potential agent against MDA-MB-231 triple-negative breast cancer cells. *Biomed Pharmacother* 178: 117249.

- Che, X., Zhang, L., 2025. Blind docking methods have been inappropriately used in most network pharmacology analysis. *Front Pharmacol* 16: 1566772.
- Cheung, A., Chenoweth, A.M., Johansson, A., *et al.*, 2024. Anti-EGFR antibody–drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth. *Clin Cancer Res* 30: 3298–3315.
- Chin, C.H., Chen, S.H., Wu, H.H., Ho, C.W., Ko, M.T., Lin, C.Y., 2014. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol* 8: S11.
- Daina, A., Michielin, O., Zoete, V., 2017. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep* 7: 42717.
- Daina, A., Michielin, O., Zoete, V., 2019. Swisstargetprediction: updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic Acids Res* 47: W357–W364.
- Darwish, M.I.M., Moustafa, A.M., Youssef, A.M., *et al.*, 2023. Novel tetrahydro-[1,2,4]triazolo[3,4-a]isoquinoline chalcones suppress breast carcinoma through cell cycle arrests and apoptosis. *Molecules* 28: 3338.
- Dave, R.A., Morris, M.E., 2016. Novel high/low solubility classification methods for new molecular entities. *Int J Pharm* 511: 111–126.
- Dhaliwal, J.S., Moshawih, S., Goh, K.W., *et al.*, 2022. Pharmacotherapeutics applications and chemistry of chalcone derivatives. *Molecules* 27: 7062.
- Egeland, E.V., Seip, K., Skourti, E., *et al.*, 2024. The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy. *Br J Cancer* 131: 1656–1667.
- El-Gewely, M., Andreassen, M., Walquist, M., Ursvik, A., Knutsen, E., Nystad, M., Coucheron, D., Myrnel, K., Hennig, R., Johansen, S., 2016. Differentially expressed microRNAs in meningiomas grades I and II suggest shared biomarkers with malignant tumors. *Cancers* 8: 31.
- Elkhalifa, D., Alali, F., Al Moustafa, A.E., Khalil, A., 2019. Targeting triple negative breast cancer heterogeneity with chalcones: a molecular insight. *J Drug Target* 27: 830–838.
- Fan, T., Huang, Y., Liu, Z., Huang, J., Ke, B., Rong, Y., Qiu, H., Zhang, B., 2024. Unveiling the mechanism of the chaishao shugan formula against triple-negative breast cancer. *DDDT* Volume 18: 1115–1131.

- Feng, Y., Spezia, M., Huang, S., *et al.*, 2018. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis* 5: 77–106.
- Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., Bray, F., 2024. Global cancer observatory: cancer today. lyon, france: international agency for research on cancer. *Global Cancer Observatory*.
- Ferreira, L., Dos Santos, R., Oliva, G., Andricopulo, A., 2015. Molecular Docking and structure-based drug design strategies. *Molecules* 20: 13384–13421.
- Fogaça, T.B., Martins, R.M., Begnini, K.R., Carapina, C., Ritter, M., De Pereira, C.M.P., Seixas, F.K., Collares, T., 2017. Apoptotic effect of chalcone derivatives of 2-acetylthiophene in human breast cancer cells. *Pharmacol Rep* 69: 156–161.
- Gao, F., Huang, G., Xiao, J., 2020. Chalcone hybrids as potential anticancer agents: current development, mechanism of action, and structure-activity relationship. *Med Res Rev* 40: 2049–2084.
- Gfeller, D., Grosdidier, A., Wirth, M., *et al.*, 2014. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. *Nucleic Acids Res* 42: W32–W38.
- Gomes, M., Muratov, E., Pereira, M., Peixoto, J., Rosseto, L., Cravo, P., Andrade, C., Neves, B., 2017. Chalcone derivatives: promising starting points for drug design. *Molecules* 22: 1210.
- Greco, S., Fabbri, N., Spaggiari, R., De Giorgi, A., Fabbian, F., Giovine, A., 2023. Update on classic and novel approaches in metastatic triple-negative breast cancer treatment: a comprehensive review. *Biomedicines* 11: 1772.
- Guo, C.H., Hsia, S., Chung, C.H., Lin, Y.C., Shih, M.Y., Chen, P.C., Hsu, G.S.W., Fan, C.T., Peng, C.L., 2021. Combination of fish oil and selenium enhances anticancer efficacy and targets multiple signaling pathways in anti-VEGF agent treated-TNBC tumor-bearing mice. *Marine Drugs* 19: 193.
- Hartanto, H.D., 2024. Sintesis dan Uji Sitotoksisitas Turunan Kalkon dan Pirazolina Berbasis 3-Asetilpiridin Terhadap Lini Sel Kanker [Undergraduate's Thesis]. Universitas Gadjah Mada, Yogyakarta.
- Huang, J., Luo, Q., Xiao, Y., Li, H., Kong, L., Ren, G., 2017. The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer. *Oncotarget* 8: 108249–108260.
- Huang, Z., Yu, P., Tang, J., 2020. Characterization of triple-negative breast cancer MDA-MB-231 cell spheroid model. *OTT Volume* 13: 5395–5405.

- Jain, A.K., Singh, D., Dubey, K., Maurya, R., Mittal, S., Pandey, A.K., 2018. Models and methods for in vitro toxicity. *In Vitro Toxicology* 45–65.
- Jain, A., Barge, A., Parris, C.N., 2025. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms. *Oncogene* 44: 193–207.
- Jin, J., Qiu, S., Wang, P., *et al.*, 2019. Cardamonin inhibits breast cancer growth by repressing HIF-1 $\alpha$ -dependent metabolic reprogramming. *J Exp Clin Cancer Res* 38: 377.
- Karim, A.M., Eun K.J., Ali, T., Jang, J., Ullah, I., Lee, Y.G., Park, D.W., Park, J., Jeang, J.W., Kang, S.C., 2023. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. *Biochem Pharmacol* 212: 115545.
- Karthikeyan, C., Narayana Moorthy, N.S.H., Ramasamy, S., Vanam, U., Manivannan, E., Karunakaran, D., Trivedi, P., 2014. Advances in chalcones with anticancer activities. *PRA* 10: 97–115.
- Katsura, C., Ogunmwonyi, I., Kankam, H.K., Saha, S., 2022. Breast cancer: presentation, investigation and management. *Br J Hosp Med* 83: 1–7.
- Kontomanolis, E.N., Koutras, A., Syllaios, A., Schizas, D., Kalagasidou, S., Pagkalos, A., Alatzidou, D., Kantari, P., Ntounis, T., Fasoulakis, Z., 2021. Basic principles of molecular biology of cancer cell-molecular cancer indicators. *J BUON* 26: 1723–1734.
- Kumar, S., Sharma, P., Kumar, S., Bawa, S., 2025. Insightful synthetic strategies and pharmacological potential of thiophene derivatives: a comprehensive review. *COC* 30.
- Kumar, P., Nagarajan, A., Uchil, P.D., 2018. Analysis of cell viability by the MTT assay. *Cold Spring Harb Protoc* 2018: pdb.prot095505.
- Kumar, P., Singh, R., Sharma, D., Hassan, Q.P., Gopu, B., Anal, J.M.H., 2024. Design, synthesis, and biological evaluation of chalcone acetamide derivatives against triple negative breast cancer. *Bioorg Med Chem Lett* 107: 129795.
- Kumari, P., Gupta, A., 2021. Assays to assess the proliferative behavior of cancer cells. *Protocol Handbook for Cancer Biology* 23–41.
- Lee, S.H., Lee, H., Kwon, Y.J., Kim, S.K., Seo, E.B., Sohn, J.O., Kim, B.H., Park, J.Y., Ye, S.K., 2025. Chalcone-9: a novel inhibitor of the JAK-STAT pathway with potent anti-cancer effects in triple-negative breast cancer cells. *Pharmacol Rep*.

- Li, C.Y., Cai, J.H., Tsai, J.J.P., Wang, C.C.N., 2020. Identification of hub genes associated with development of head and neck squamous cell carcinoma by integrated bioinformatics analysis. *Front. Oncol.* 10: 681.
- Lieberman, M.M., Patterson, G.M.L., Moore, R.E., 2001. In vitro bioassays for anticancer drug screening: effects of cell concentration and other assay parameters on growth inhibitory activity. *Cancer Lett* 173: 21–29.
- Lin, J., Song, T., Li, C., Mao, W., 2020. GSK-3 $\beta$  in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. *Biochim Biophys Acta Mol Cell Res* 1867: 118659.
- Ling, J., Kumar, R., 2012. Crosstalk between NF $\kappa$ B and glucocorticoid signaling: a potential target of breast cancer therapy. *Cancer Lett* 322: 119–126.
- Lu, S., Sun, X., Zhou, Z., *et al.*, 2023. Mechanism of bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation. *Front. Immunol.* 14: 1235575.
- Luo, Y., Wu, W., Zha, D., *et al.*, 2021. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents. *Bioorg Med Chem Lett* 47: 128230.
- Mohamed, M.F.A., Shaykoon, M.Sh.A., Abdelrahman, M.H., Elsadek, B.E.M., Aboraia, A.S., Abuo-Rahma, G.E.-D.A.A., 2017. Design, synthesis, docking studies and biological evaluation of novel chalcone derivatives as potential histone deacetylase inhibitors. *Bioorg Chem* 72: 32–41.
- Mphahlele, M.J., More, G.K., Maluleka, M.M., Choong, Y.S., 2023. Bio-evaluation of the 2-nitrochalcones as potential anti-lung cancer agents, inducers of apoptosis and inhibitors of protein kinase (VEGFR-2). *Med Chem Res* 32: 2380–2393.
- Mustofa, M, Satriyo, P.B., Suma, A.A.T., Waskitha, S.S.W., Wahyuningsih, T.D., Sholikhah, E.N., 2022. A potent EGFR inhibitor, N-Phenyl Pyrazoline derivative suppresses aggressiveness and cancer stem cell-like phenotype of cervical cancer cells. *DDDT* Volume 16: 2325–2339.
- Nhlapho, S., Nyathi, M., Ngwenya, B., Dube, T., Telukdarie, A., Munien, I., Vermeulen, A., Chude-Okonkwo, U., 2024. Druggability of pharmaceutical compounds using lipinski rules with machine learning. *sciphar* 3: 177–192.
- Niu, M., Valdes, S., Naguib, Y.W., Hursting, S.D., Cui, Z., 2016. Tumor-Associated macrophage-mediated targeted therapy of triple-negative breast cancer. *Mol Pharm* 13: 1833–1842.
- Ouyang, Y., Li, J., Chen, X., Fu, X., Sun, S., Wu, Q., 2021. Chalcone derivatives: role in anticancer therapy. *Biomolecules* 11: 894.

- Padauleng, N., 2023. Potensi senyawa kalkon-3 sebagai antikanker payudara: kajian aktivitas molekuler in vitro pada galur sel T-47D, MCF-7, MDA-MB-231, dan in vivo pada tikus yang diinduksi DMBA [Disertation]. Universitas Gadjah Mada, Yogyakarta.
- Padauleng, N., Mustofa, M., Wahyuningsih, T., Purnomosari, D., 2023. Chalcone-3 inhibits the proliferation of human breast cancer MDA-MB-231 cell line. *Asian Pac J Cancer Prev* 24: 683–691.
- Parks, M., Yu, X., Peng, Y., Bhambhani, J., Hsu, D., Ranasinghe, D., Kucukbenli, E., Tam, H.H., 2025. Blind virtual screening at scale: a scalable end-to-end pipeline for blind docking and affinity prediction. .
- Pawlak, A., Henklewska, M., Hernández Suárez, B., Łużny, M., Kozłowska, E., Obmińska-Mrukowicz, B., Janeczko, T., 2020. Chalcone methoxy derivatives exhibit antiproliferative and proapoptotic activity on canine lymphoma and leukemia cells. *Molecules* 25: 4362.
- Pinero, J., Queralt-Rosinach, N., Bravo, A., Deu-Pons, J., Bauer-Mehren, A., Baron, M., Sanz, F., Furlong, L.I., 2015. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. *Database (Oxford)* 2015: bav028–bav028.
- Piñero, J., Saüch, J., Sanz, F., Furlong, L.I., 2021. The DisGeNET cytoscape app: exploring and visualizing disease genomics data. *Comput Struct Biotechnol J* 19: 2960–2967.
- Pinto, P., Machado, C.M., Moreira, J., *et al.*, 2019. Chalcone derivatives targeting mitosis: synthesis, evaluation of antitumor activity and lipophilicity. *Eur J Med Chem* 184: 111752.
- Pinzi, L., Rastelli, G., 2019. Molecular docking: shifting paradigms in drug discovery. *Int J Mol Sci* 20: 4331.
- Purnomosari, D., Nabila, B.Z., Widyarini, S., Mustofa., 2025. Targeting immune cells in tumor microenvironment in triple negative breast cancer therapy: future perspective to overcome doxorubicin resistance and toxicity. *Med Oncol* 42: 150.
- Qiu, X., Deng, C., Ma, D., Xiao, M., Huang, T., Zhu, Q., Song, H., 2025. Exploring the adsorption behavior and structure–activity relationships of a poly(ionic liquid) with phenolic compounds having varied substituent types and positions. *Chemical Engineering Science* 310: 121526.
- Reddy, L.S.S., Raju, M.B., Sridhar, C., 2016. Novel pyrazolines: synthesis and evaluation of their derivatives with anticancer and anti-inflammatory activities. *Int J Pharm Pharm Sci* 8.

- Riza, N.F., 2025. Synthesis of N-phenylpyrazoline derivatives from 2-acetyl-5-chlorothiophene and their activity assay as anticancer agents [Master's Thesis]. Universitas Gadjah Mada, Yogyakarta.
- Roskoski, R., 2019. Properties of FDA-approved small molecule protein kinase inhibitors. *Pharmacol Res* 144: 19–50.
- Roy, M., Fowler, A.M., Ulaner, G.A., Mahajan, A., 2023. Molecular classification of breast cancer. *PET Clinics* 18: 441–458.
- Rudrapal, M., Khan, J., Dukhyil, A.A.B., Alarousy, R.M.I.I., Attah, E.I., Sharma, T., Khairnar, S.J., Bendale, A.R., 2021. Chalcone scaffolds, bioprecursors of flavonoids: chemistry, bioactivities, and pharmacokinetics. *Molecules* 26: 7177.
- Sardar, H., 2023. Drug like potential of daidzein using SwissADME prediction: In silico Approaches. *PHYTONutrients* 01–07.
- Sargazi, S., Abghari, A.Z., Sarani, H., Sheervalilou, R., Mirinejad, S., Saravani, R., Eskandari, E., 2021. Relationship between CASP9 and CASP10 gene polymorphisms and cancer susceptibility: evidence from an updated meta-analysis. *Appl Biochem Biotechnol* 193: 4172–4196.
- Satriyo, P.B., Mustofa, M., Wahyuningsih, T.D., Damayanti, E., Wiraswati, H.L., Satria, D., Bashari, M.H., Sholikhah, E.N., 2024. N-phenyl pyrazoline derivative inhibits cell aggressiveness and enhances paclitaxel sensitivity of triple negative breast cancer cells. *Sci Rep* 14: 13200.
- Satriyo, P.B., Mustofa, M., Wahyuningsih, T.D., Damayanti, E., Wiraswati, H.L., Satria, D., Bashari, M.H., Sholikhah, E.N., 2024. N-phenyl pyrazoline derivative inhibits cell aggressiveness and enhances paclitaxel sensitivity of triple negative breast cancer cells. *Sci Rep* 14: 13200.
- Scialla, S., Hanafy, M.S., Wang, J.-L., Genicio, N., Costa Da Silva, M., Costa, M., Oliveira-Pinto, S., Baltazar, F., Gallo, J., Cui, Z., Bañobre-López, M., 2023. Targeted treatment of triple-negative-breast cancer through pH-triggered tumour associated macrophages using smart theranostic nanoformulations. *Int J Pharm* 632: 122575.
- Sharma, P., Kumar, S., Ali, F., Anthal, S., *et al.*, 2013. Synthesis and biologic activities of some novel heterocyclic chalcone derivatives. *Med Chem Res* 22: 3969–3983.
- Sharom, F.J., 2014. Complex interplay between the p-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function. *Front Oncol* 4.

- Singh, D.D., Yadav, D.K., 2021. TNBC: Potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy. *Biomedicines* 9: 876.
- Solomon, V.Raja., Lee, H., 2012. Anti-breast cancer activity of heteroaryl chalcone derivatives. *Biomed Pharmacother* 66: 213–220.
- Stepanenko, A.A., Dmitrenko, V.V., 2015. Pitfalls of the MTT assay: Direct and off-target effects of inhibitors can result in over/underestimation of cell viability. *Gene* 574: 193–203.
- Sun, X., Tang, H., Chen, Y., Chen, Z., Hu, Z., Cui, Z., Tao, Y., Yuan, J., Fu, Y., Zhuang, Z., He, Q., Li, Q., Xu, X., Wan, X., Jiang, Y., Mao, Z., 2023. Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer. *Nat Cancer* 4: 716–733.
- Tri Suma, A.A., Dwi Wahyuningsih, T., Mustofa., 2019. Efficient synthesis of chloro chalcones under ultrasound irradiation, their anticancer activities and molecular docking studies. *Rayasan J Chem* 12: 502–510.
- Tu, H.Y., Huang, A.M., Hour, T.C., Yang, S.C., Pu, Y.S., Lin, C.N., 2010. Synthesis and biological evaluation of 2',5'-dimethoxychalcone derivatives as microtubule-targeted anticancer agents. *Bioorg Med Chem* 18: 2089–2098.
- Vagia, E., Mahalingam, D., Cristofanilli, M., 2020. The landscape of targeted therapies in TNBC. *Cancers* 12: 916.
- Vasconcelos, A.D, Campos, V.F., Nedel, F., Seixas, F.K., Dellagostin, O.A., Smith, K.R., De Pereira, C.M.P., Stefanello, F.M., Collares, T., Barschak, A.G., 2013. Cytotoxic and apoptotic effects of chalcone derivatives of 2-acetyl thiophene on human colon adenocarcinoma cells. *Cell Biochem Funct* 31: 289–297.
- Waks, A.G., Winer, E.P., 2019. Breast Cancer Treatment: A Review. *JAMA* 321: 288.
- Wang, G., Liu, W., Gong, Z., Huang, Y., Li, Y., Peng, Z., 2020. Design, synthesis, biological evaluation and molecular docking studies of new chalcone derivatives containing diaryl ether moiety as potential anticancer agents and tubulin polymerization inhibitors. *Bioorg Chem* 95: 103565.
- Wang, L., Wang, Z., Ni, Y., Wang, X., Zhang, T., Hu, M., Lian, C., Wang, X., Zhang, J., 2024. Elucidating the mechanism of action of Isobavachalcone induced autophagy and apoptosis in non-small cell lung cancer by network pharmacology and experimental validation methods. *Gene* 918: 148474.

- Wang, M., Xu, S., Wu, C., Liu, X., Tao, H., Huang, Y., Liu, Y., Zheng, P., Zhu, W., 2016. Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit. *Bioorg Med Chem. Lett* 26: 5450–5454.
- Wang, Z., Wang, N., Han, S., Wang, D., Mo, S., Yu, L., Huang, H., Tsui, K., Shen, J., Chen, J., 2013. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. *PLoS ONE* 8: e68566.
- Widiandani, T., Tandian, T., Zufar, B.D., Suryadi, A., Purwanto, B.T., Hardjono, S., Siswandono, S., 2023. In vitro study of pinostrobin propionate and pinostrobin butyrate: Cytotoxic activity against breast cancer cell T47D and its selectivity index. *J. Public Health Afr.* 14: 6.
- Wilkinson, L., Gathani, T., 2022. Understanding breast cancer as a global health concern. *Br J Radiol* 95: 20211033.
- Wulan, F.F., Astuti, E., Prasetyo, N., Kumar, N., Wahyuningsih, T.D., 2025. Investigating chlorothiophene-based chalcones as anticancer agents: Synthesis, biological evaluation, and computational insight via the p53-targeted pathway. *Arab J Chem.*
- Xiong, X., Zheng, L.W., Ding, Y., *et al.*, 2025. Breast cancer: pathogenesis and treatments. *Sig Transduct Target Ther* 10: 49.
- Yang, Z., Zhang, Q., Yu, L., Zhu, J., Cao, Y., Gao, X., 2021. The signaling pathways and targets of traditional chinese medicine and natural medicine in triple-negative breast cancer. *J Ethnopharmacol* 264: 113249.
- Yin, L., Duan, J.J., Bian, X.W., Yu, S., 2020. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Res* 22: 61.
- Zeinizade, E., Tabei, M., Shakeri-Zadeh, A., Ghaznavi, H., Attaran, N., Komeili, A., Ghalandari, B., Maleki, S., Kamrava, S.K., 2018. Selective apoptosis induction in cancer cells using folate-conjugated gold nanoparticles and controlling the laser irradiation conditions. *Artif. Cells Nanomed. Biotechnol* 46: 1026–1038.
- Zhang, H., Jiang, R., Zhu, J., Sun, K., Huang, Y., Zhou, H., Zheng, Y., Wang, X., 2024. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. *Breast Cancer* 31: 539–551.
- Zhu, P., Liu, G., Wang, X., *et al.*, 2022. Transcription factor c-Jun modulates GLUT1 in glycolysis and breast cancer metastasis. *BMC Cancer* 22: 1283.
- Zhuang, C., Zhang, W., Sheng, C., Zhang, W., Xing, C., Miao, Z., 2017. Chalcone: a privileged structure in medicinal chemistry. *Chem. Rev.* 117: 7762–7810.